Clinical trials
Multiple Sclerosis, Primary Progressive clinical trials
Below are recruiting multiple sclerosis, primary progressive clinical trials, each written for real people, not researchers. We’re tracking 71 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06495138Recruiting
Eye exercises for dizziness in multiple sclerosis
This study tests a new type of eye exercise to help with dizziness and balance problems in people with multiple sclerosis (MS). The exercise involves moving your head and eyes in a specific way to retrain your balance system.
Atlanta, GeorgiaAges 18–89 - NCT06629428RecruitingEarly Phase 1
Study of ublituximab for walking and movement in multiple sclerosis
This trial tests if ublituximab can improve walking and other motor skills in people with active relapsing MS. You must be able to walk at least 25 feet and stand 30 seconds on your own.
Atlanta, GeorgiaAges 18–55 - NCT06592703RecruitingPhase 1
Stem cells for primary progressive MS
This study tests whether stem cells from donated fat tissue can slow down primary progressive multiple sclerosis. You would receive a single injection of the cells into your spinal fluid and be followed for up to 2 years.
CréteilAges 18–55 - NCT06526364Recruiting
Multiple sclerosis study with smartphone app tracking
This study follows people with multiple sclerosis over time using a smartphone app and clinic visits. It aims to better understand the disease and improve care.
BaselAges 18 years+ - NCT06495593Enrolling by invitationPhase 4
Ocrelizumab's effect on immune cells in lymph nodes in MS
This study tests how ocrelizumab, a medication for MS, affects immune cells in your lymph nodes. It may help doctors understand how the drug works and why it helps some people more than others.
San Francisco, CaliforniaAges 18–65 - NCT06221631Recruiting
Brain aging in MS and healthy people
This study compares how the brain ages in people with multiple sclerosis (MS) and healthy volunteers. It uses MRI scans and other tests to understand brain aging better.
Bern, Canton of BernAges 18–65 - NCT06138132RecruitingPhase 1
CAR-T cell therapy for progressive multiple sclerosis
This trial is testing a type of immunotherapy called CAR-T cells (made from your own immune cells) to see if it can help slow or stop progressive multiple sclerosis. It is a very early safety study, so only people with progressive MS who meet strict health criteria can join.
Palo Alto, CaliforniaAges 18–65 - NCT05758831RecruitingPhase 3
Rituximab vs ocrelizumab for relapsing multiple sclerosis
This trial compares rituximab and ocrelizumab in people with relapsing-remitting multiple sclerosis (MS) to see which medicine better controls MS activity. It may help reduce future relapses and new MRI lesions.
Lyon, BronAges 18–55 - NCT05748015Recruiting
Checking how the nervous system is affected in multiple sclerosis
This study looks at signs of how your automatic “control” nerves (the autonomic nervous system) may be affected in people with multiple sclerosis. It may help researchers better understand different types of MS and how to recognize nervous-system involvement.
Telese Terme, BeneventoAges 18 years+ - NCT05386394RecruitingPhase 2
Brain stimulation to help primary progressive aphasia speech
This trial tests a non-painful brain stimulation method to improve language and speech problems caused by primary progressive aphasia. It may help some people communicate more clearly by targeting specific brain regions.
Baltimore, MarylandAges 50–90 - NCT05359653RecruitingPhase 1/Phase 2
Clemastine to study MRI changes in relapsing MS
This early-phase study tests whether clemastine (a drug being studied for “myelin repair”) changes how MS looks on special MRI scans. It may help researchers understand if the treatment supports restoring nerve covering in people with relapsing-remitting MS.
San Francisco, CaliforniaAges 18–55 - NCT05061953Recruiting
Eye-tracking test software study in adults with multiple sclerosis
This study checks how well new eye-tracking software can measure eye movements in people with multiple sclerosis. It may help researchers track changes in how the nervous system works using a simple camera-based eye test.
Montreal, QuebecAges 18 years+ - NCT03900221Recruiting
Pregnancy monitoring registry for multiple sclerosis in France
This study follows people who are pregnant and have multiple sclerosis (or related conditions) to better understand what happens during pregnancy. It does not appear to test a new treatment; it mainly collects health and pregnancy information.
AmiensAges Any age - NCT04047628RecruitingPhase 3
MS patients with active relapsing disease comparing two treatment plans
This Phase 3 study compares the best standard MS treatment (chosen by your doctors) versus an approach called autologous hematopoietic stem cell transplant (AHSCT) for people with highly active, treatment-resistant relapsing multiple sclerosis. It aims to see which option controls MS disease activity better and keeps you safer over time.
Palo Alto, CaliforniaAges 18–55 - NCT03783416RecruitingPhase 1
Ixazomib safety study for people with multiple sclerosis
This early-phase study tests how safe ixazomib is for people with multiple sclerosis (MS). It focuses on targeting certain immune cells in MS and checks whether the treatment can be given safely.
London, Greater LondonAges 18–65 - NCT03600779Recruiting
Advanced MRI scan for multiple sclerosis
This study uses a special MRI scan to look at brain damage caused by multiple sclerosis (MS). It may help doctors better understand the disease and could lead to better treatments.
Marseille, PACAAges 18–45 - NCT04920318Recruiting
Study to improve language in primary progressive aphasia
This trial looks at ways to improve language abilities in people with primary progressive aphasia (a long-term brain condition that affects speech and language). It may help if your communication problems come from this condition and you can safely take part in the study activities, which likely involve language practice and MRI scanning.
Tucson, ArizonaAges 45–80 - NCT07503873RecruitingPhase 2
Study of ublituximab injection for multiple sclerosis
This trial tests a new way to give the drug ublituximab (an injection under the skin) to people with relapsing multiple sclerosis. It compares different injection sites and a special auto-injector device to see how the body absorbs the drug and if it's safe.
BihaćAges 18–65 - NCT06964581Recruiting
At-home cognitive training for multiple sclerosis
This study tests a at-home thinking and memory training program for people with multiple sclerosis. It aims to help improve mental skills like memory, attention, and planning through remote sessions.
Verona, veronaAges 18–65 - NCT07011914Recruiting
MS care study for young adults
This study looks at how to improve care for young adults with relapsing-remitting MS. It focuses on people who are Black, Hispanic, or have limited income.
Birmingham, AlabamaAges 18 years+ - NCT06901687RecruitingPhase 2
Home brain stimulation for depression in MS
This study tests whether a special, gentle brain stimulation device you can use at home (called tDCS) can help improve depression symptoms in people with multiple sclerosis. You will be supervised over video during the sessions to make sure everything goes smoothly.
New York, New YorkAges 18–65 - NCT06846281RecruitingPhase 3
Remibrutinib for relapsing multiple sclerosis after switching from Ocrevus
This study tests a new oral medication called remibrutinib for people with relapsing multiple sclerosis who are currently on Ocrevus. Participants will switch from Ocrevus to remibrutinib to see if it is safe and effective.
Scottsdale, ArizonaAges 40–70 - NCT07161258RecruitingPhase 2
Fenebrutinib for children with relapsing MS
This study tests a new oral medication called fenebrutinib for children and teenagers with relapsing multiple sclerosis. It aims to find the right dose and see how safe and effective it is compared to standard treatments.
Rosario, Santa Fe ProvinceAges 10–17 - NCT05906992RecruitingPhase 3
Testing CT-P53 versus Ocrevus for relapsing MS
This Phase 3 study compares CT-P53 with Ocrevus in people with relapsing-remitting multiple sclerosis (MS). It aims to see how well each treatment controls MS activity and to compare safety and study drug effects.
PoznanAges 18–55
Hear when a new Multiple Sclerosis, Primary Progressive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for multiple sclerosis, primary progressive?
- Yes. Clin2 currently lists 71 recruiting multiple sclerosis, primary progressive studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a multiple sclerosis, primary progressive trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a multiple sclerosis, primary progressive trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Multiple Sclerosis (MS) Primary Progressive
- Multiple Sclerosis, Secondary Progressive
- Progressive Multiple Sclerosis
- Multiple Sclerosis (MS) Secondary Progressive
- Multiple Sclerosis, Chronic Progressive
- Multiple Sclerosis, Relapsing-Remitting
- Primary Progressive Aphasia
- Multiple Sclerosis (MS) - Relapsing-remitting
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.